Advanced Search

Home > Journals > Minerva Urologica e Nefrologica > Past Issues > Minerva Urologica e Nefrologica 2013 December;65(4) > Minerva Urologica e Nefrologica 2013 December;65(4):249-62

ISSUES AND ARTICLES   MOST READ   eTOC

CURRENT ISSUEMINERVA UROLOGICA E NEFROLOGICA

A Journal on Nephrology and Urology

Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,536

Frequency: Bi-Monthly

ISSN 0393-2249

Online ISSN 1827-1758

 

Minerva Urologica e Nefrologica 2013 December;65(4):249-62

ADVANCES IN UROLOGY - PART I 

Intravesical glycosaminoglycans in the management of chronic cystitis

Iacovelli V., Topazio L., Gaziev G., Bove P., Vespasiani G., Finazzi Agrò E.

Department of Urology, Tor Vergata University of Rome, Rome, Italy

In this article we review the current status of evidence on the clinic applications of glycosaminoglycans (GAGs) in urology, with particular emphasis on the therapeutic use in all the chronic forms of cystitis. The so called “bladder layer” is mainly composed by chondroitin sulphate, dermatan sulphate and heparan sulphate. Demages of this mucus film seem to be involved in the pathogenesis of several bladder diseases. Hence, GAG replenishment therapy is widely accepted as a therapy for interstitial cystitis/ bladder pain syndrome (IC/BPS), recurrent urinary tract infections (UTIs), radiation and chemo-immunotherapy cystis and overactive bladder (OAB). A MEDLINE search from the first clinical application in 1996 allowed us to find a total of 33 works regarding the use of intravesical GAGs. Although the evidences regarding GAG replenishment therapy are very encouraging in all the forms of chronic cystitis, well-powered randomized clinical trials are needed to better comprehend the exact role of this treatment.

language: English


FULL TEXT  REPRINTS

top of page